

Jefferson Cancer Network News



Jefferson Cancer Network

Albert Einstein Medical Center
 Alfred I. duPont Hospital for Children
 Brandywine Hospital
 Ephrata Community Hospital
 Frankford Hospitals
 Hematology & Oncology Associates of
 Northeastern PA PC
 Hudson Valley Oncology Associates
 Jefferson Hospital for Neuroscience
 Kimmel Cancer Center at Jefferson
 Jefferson Radiation Oncology Center
 at Chestnut Hill
 Jefferson Radiation Oncology Center
 at Lower Bucks
 Memorial Hospital of Salem County
 Mercy Fitzgerald Hospital
 Mercy Hospital of Philadelphia
 Mercy Suburban Hospital
 Methodist Hospital
 Montgomery Hospital Medical Center
 Northeast Radiation Oncology Center
 Pocono Medical Center
 Riddle Memorial Hospital
 Sacred Heart Hospital
 Sparta Cancer Treatment Center
 Underwood-Memorial Hospital
 Upper Delaware Valley Cancer Center
 Wills Eye at Jefferson

Working Together in Cancer Care,
 Education and Research

Message from the Clinical Director, Walter J. Curran Jr., MD

I am pleased to present the Spring 2007 issue of the Jefferson Cancer Network News. As our cancer network begins its 15th year in operation, it is clear that we have much work yet to do to increase awareness and clinical trial participation. Our coordinators are working with the member investigators and research coordinators to ensure that they have access to trials that fit the needs of their patient population. Please let us know what else we can do to ensure that clinical trials are available to all patients in our network. Feel free to email me or Patricia Dugan at walter.curran@jefferson.edu and patricia.dugan@jeffersonhospital.org, respectively with any suggestions.

I hope you will enjoy "meeting" our featured investigators in this issue. I am happy to report that Dr. Cheryl Gardner of Ephrata

recently received a certificate of recognition from the JCN for her efforts in clinical trial enrollments in 2006.

The complete list of recognition awards for 2006 is as follows:

For highest overall institutional accrual; Albert Einstein Cancer Center, Hematology & Oncology Associates of NEPA, Alfred I. duPont Hospital for Children, Frankford Hospitals and Pocono Medical Center.

Recognition awards for the highest number of patients enrolled by investigator went to Dr. William Tester of the Albert Einstein Cancer Center, Dr. William Heim of Hematology & Oncology Associates of NEPA, Dr. Michael Greenberg of Pocono Medical Center, Dr. Cheryl Gardner of Ephrata Cancer Center, and Drs. Jonathon Powell and Gregory Griffin both of duPont Hospital for Children.

Recognition for timely data submission was awarded to Sally Wagenborg of Frankford Hospitals, Dan Ward of Ephrata Cancer Center and Betsy Mead & LeeAnn Haefele both of Hematology & Oncology Associates of NEPA.

Congratulations to all for your hard work and success in 2006!

Featured Clinical Trials: NSABP B-42, TAILORx and NSABP FRP FB-4

NSABP B-42 is a phase III randomized, placebo-controlled, double-blind study to determine if prolonged adjuvant hormonal therapy with letrozole will improve disease-free survival in postmenopausal women with ER-positive and/or PgR-positive breast cancer who have completed 5 years of hor-

monal therapy with either an aromatase inhibitor (AI) or up to 3 years of tamoxifen followed by an AI.

TAILORx stands for "Trial Assigning Individualized Options for Treatment (Rx)" and it is a clinical research trial for women with early-stage

breast cancer. The purpose is to individualize cancer treatment by using modern diagnostic tests that have not previously been routinely used in clinical practice. This trial is expected to accrue 11,000 women.

NSABP FRP FB-4 is a phase II clinical trial of bevacizumab

beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with locally advanced breast cancer.

Calendar

April 27 – 30, 2007

NSABP Group Meeting
 Jacksonville, FL
www.nsabp.pitt.edu

May 2 – 3, 2007

SELECT Group Meeting
 Chicago, IL
www.swog.org

June 8 – 10, 2007

ECOG Group Meeting
 Washington, DC
www.ecog.dfc.harvard.edu

June 16, 2007

Comprehensive ASCO Review
 Philadelphia Loews Hotel

June 20, 2007

Clinical Research
 Associates Update
 Bluemle 105

June 21 – 24, 2007

RTOG Group Meeting
 Philadelphia Loews Hotel
www.rtog.org

SUBMIT AN ARTICLE
 Contact the editor,
 Colleen M. Cohick, MPH, at
colleen.cohick@jefferson.edu

**WE'VE
 MOVED!**

Please note that the JCN has recently moved to a new location on campus. We are now located at 1015 Chestnut Street, Suite 622. Telephone numbers are the same, but we have a new fax number, 215-955-1020.

HDQ Update

Genetic Counselor, **Sarah Charles, MS**, is a recent addition to the JCN team. As a provider of genetic consultation services, she works closely with the network institutions in the coordination of molecular genetic testing and appropriate follow-up for patients in whom a hereditary cancer syndrome is suspected. For more information or to refer a patient, Sarah can be contacted at 215-955-1011 or sarah.charles@jeffersonhospital.org.

Congratulations to **Fran Guiles, RHIA, CTR**, Manager of Oncology Data Services at TJUH. She has been elected the Vice-President of the Pennsylvania Association of Cancer Registrars (PACR).

35th Annual Bike-A-Thon

On Sunday, July 15, 2007, over 4,000 cyclists will pedal their way toward a cure through the American Cancer Society's Bike-a-thon. The Bike-a-thon is a noncompetitive cycling event to raise awareness and dollars to fight cancer. It's held rain or shine. The JCN would like to create a team. If you are interested please contact 215-456-3802 or email bowsn@einstein.edu.

Open JOG Trials

JOG 030 A Phase 2 Trial of Cloretazine for Patients with Relapsed or Refractory SCLC

JOG 031 An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 in Combo with Cisplatin compared against 5-FU in Combo with Cisplatin in Patients with Advanced Gastric Cancer previously Untreated with Chemotherapy for Advanced Disease

JOG 032 A Randomized Study of Intermittent Capecitabine In Combination With Oxaliplatin (XeloxQ3W) and Bevacizumab versus Intermittent Capecitabine in Combination with Oxaliplatin (XeloxQ2W) and Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer.

JOG 033 A Multicenter, Open-Label, Single-Arm, 2-Stage Phase II Study of the Efficacy and Safety of AVE00005 Administered Intravenously Every 2 Weeks in Subjects with Platinum, Taxane, and Erlotinib-Resistant Advanced NSCL Adenocarcinoma

JOG 034 A Randomized, Open-Label, Phase 3 Trial of NOV-002 in Combo with Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin alone for the Treatment of Advanced NSCLC

JOG 035 A Randomized, Double-Blind, Placebo Controlled Study evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects with Low or Intermediate-1

Risk MDS receiving Hypomethylating Agents

JOG 036 A Randomized Phase 3 Trial of ALIMTA and Carboplatin vs Etoposide and Carboplatin in Extensive-Stage SCLC

JOG 037 A Randomized, Open-Label, Controlled Phase 2 Trial of Docetaxel and Cisplatin Combination Chemotherapy with and without Panitumumab in the First-Line Treatment of Subjects with Metastatic or Recurrent H&N Cancer

JOG 038 Induction Therapy for Locally Advanced, Resectable Cancer of the Esophagus, GE Junction and Gastric Cardia: A Phase I Trial of ZD6474 Paclitaxel, Carboplatin, 5-FU, and XRT followed by Surgery

Putting Patients First

Elizabeth "Michelle" Quinones was just named Albert Einstein Cancer Center's Office Manager. She works to raise the level of cancer awareness among Latinos. Serving as a certified spanish-english interpreter is only part of what Michelle brings to her position each day. She was recently featured in The Redes Report, the newsletter of the National Latino Cancer Research Network. Michelle who has been working at AEMC community cancer center for the past 5 years helps the patients navigate the cumbersome man-

aged care system, assists them with the referral process, addresses difficult questions about medical coverage, instructions for medications, procedures and treatment.

Largest-Ever Recorded Decline in Cancer Deaths

The number of deaths from cancer saw the largest drop ever recorded between 2003 and 2004, according to an American Cancer Society report. The report found that there were 3,014 fewer cancer deaths in the US in 2004 than there were in 2003. The numbers represent a dramatic drop from those seen in 1990 and 1991, when death rates from cancer hit their peak. Cancer death rates since then have declined by 16% among men and 8.5% in women. "This success is the outcome of an investment made by the US and other governments in medical research," said **Richard Pestell, MD, PhD**, director of the KCC at Jefferson. "Cancer, like every problem, can be beaten through determined wills, clear thinking and collaboration."

Learning to Live Better with the Stress of Cancer

The Jefferson Myra Brind Center of Integrative Medicine at TJU is enrolling eligible women who are at least 21, and have been diagnosed with cancer within the last 3 years into a research study to learn skills for living better with the stress of cancer. This free 8-week study includes program materials and free parking and/or public transportation. To find out more info, call 1-800-JEFF-NOW.

Call For Volunteers

It won't be long before Riddle Memorial Hospital's webbed footed friends are racing down the creek trying to get to the finish line and beyond at the Cancer Survivor Walk & Duck Race. The Walk/Race is planned for Saturday, June 9, 2007 at the Newlin Grist Mill at US Route 1 and Cheyney Road in Glen Mills. If you would like to volunteer please call the Research Nurse, **Lorie Matson, BSN**, at 610-627-4480. All you need is a smile and an interest in doing something that can make a difference in someone's life, even if it may be for only one day.



JG 07.1936



Cheryl Gardner, DO; Wilfred Layne, MD; So Hyang Park, MD; Dan Ward, RN

Meet the PIs: Ephrata Cancer Center

Wilfred Layne, MD serves as the principal investigator and Medical Director at Ephrata Cancer Center. He is a medical oncologist and has been at Ephrata since 2002. Dr. Layne received his MD from St. George's University of School of Medicine. He completed his fellowship at SUNY.

Cheryl Gardner, DO joined Ephrata in 2001. She earned her Doctorate of Osteopathic Medicine from the Philadelphia College of Osteopathic Medicine. Dr. Gardner completed her internship and residency at Delaware Valley Medical Center, and her fellowship at SUNY.

So Hyang Park, MD is a graduate of Kyung Pook National University, School of Medicine, Taegu,

Korea. She completed her fellowship at the University of Maryland, and has been practicing at Ephrata since 2002.

All the physicians are board certified in internal medicine, hematology, and medical oncology.

Dan Ward, RN is the clinical research nurse at the cancer center. He is a graduate of Reading Area Community College and has enjoyed working at Ephrata since 2003.



Thomas Jefferson University



Thomas Jefferson University Hospital